All In Biotech

Free tool

FAERS Monitor: Akovaz

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208289 or its brand name (Akovaz, Ephedrine Sulfate). Reports on generic versions are filed under their own applications.

Reports

162

Serious

117

72% of reports

Hospitalization

46

Death reported

22

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective25
  • drug abuse14
  • cardiac arrest13
  • toxicity to various agents13
  • overdose12
  • respiratory arrest11
  • administration related reaction10
  • hypotension10
  • no adverse event10
  • off label use10
  • drug hypersensitivity9
  • nausea8
  • pain8
  • acute kidney injury7
  • anxiety7

Reports by year received

View as table
YearReports
20064
20084
20092
20106
20112
20121
20131
20144
20151
20165
20178
201820
201913
202010
202115
20228
202317
202418
202513
202610

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,997 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
administration related reactionSignal107025.03788.860,132
respiratory arrestSignal1151.929.3499
drug abuseSignal1421.813.2259
cardiac arrestSignal1320.412.1222
toxicity to various agentsSignal1310.05.997
overdoseSignal127.24.259
no adverse eventSignal107.23.947
hypotensionSignal106.53.641
drug hypersensitivitySignal96.03.233
acute kidney injurySignal75.92.924
anxietySignal73.21.59
drug ineffectiveSignal252.51.722
pain81.70.92
off label use101.50.81
nausea81.30.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.